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spective there was no blinding of the nurses or clinicians to
clopidogrel and aspirin exposure.
This lack of blinding is crucial to determine whether the main
outcomes of the study are credible. The investigators acknowl-
edged that recording of blood loss may be biased, but so could the
decision to use blood and blood products (guidelines for the use of
blood and blood products were not stated in their report). Also, no
data were provided on the use of antifibrinolytic drugs. Use of
drugs like aprotinin and tranexamic acid in patients with a high
risk of bleeding is now well established, and this data would be
relevant, particularly in patients who underwent re-exploration
(2–4). Moreover, although the Society of Thoracic Surgeons’
guidelines for re-exploration were used, these are open to inter-
pretation, and the decision of a surgeon not blinded to clopidogrel
therapy may be biased.
In addition, there was no measure of platelet function to
demonstrate the fact that platelet aggregation was different be-
tween the two groups preoperatively and that this difference
persists postoperatively and therefore directly accounts for the
difference in postoperative bleeding and other outcome measures
used. This is particularly important because the time from last
clopidogrel dose to surgery ranged from 0 to 7 days, and in some
patients, particularly those in whom clopidogrel therapy was
stopped at least 5 days before surgery, other factors may have
caused bleeding. In the Clopidogrel in Unstable Angina to prevent
Recurrent Ischaemic Events (CURE) trial, patients in whom
clopidogrel therapy was halted less than five days before surgery
had a trend toward more major bleeding than those on placebo
(9.6% vs. 6.3%, p  0.06), whereas this trend was not seen in
patients in whom surgery was performed more than five days after
clopidogrel therapy was stopped (5).
In our experience, patients on clopidogrel and aspirin up to the
time of surgery can be operated on safely provided a pro-coagulant
drug like aprotinin or tranexamic acid is used intraoperatively. As
discussed by Hongo et al. (1), antiplatelet therapy that is continued
up to the time of surgery may be beneficial; in the case of aspirin
it may improve mortality (6), and clopidogrel may reduce platelet
activation owing to cardiopulmonary bypass (7,8). Until the
question of the role of a pro-coagulant and platelet-protective drug
(9) like aprotinin is defined, it is premature to conclude that
surgery for patients with a history of clopidogrel exposure within
seven days of operation should be delayed.
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REPLY
We are pleased that Dr. Akowuah and colleagues found our study
(1) of interest. We acknowledge the inherent limitations of the
study design, and we reiterate that further studies are needed to
better define the role of clopidogrel before coronary artery bypass
grafting (CABG) surgery. We believe it premature, however, to
dismiss the credibility of the main outcomes of this study based on
the lack of blinding. Chest tube output, the main measure of
postoperative bleeding, is a highly objective and straightforward
measurement. Because the nurses who recorded the amount of
drainage were not aware of the questions being evaluated by the
study, we have no reason to believe there was motive for misrep-
resentation. Reoperation for bleeding, the main clinical outcome,
although a more subjective end point, was directed by institutional
clinical guidelines. Patients went for reoperation when chest tube
outputs either exceeded 300 ml over 2 consecutive h, or 500 ml
over 1 h. As seen in Figure 1 of our study (1), patients with
clopidogrel exposure who underwent reoperation all had 24-h
chest tube outputs in excess of 4,000 ml, notably more than that of
other patients.
The concern raised by Dr. Akowuah and colleagues regarding
the use of antifibrinolytic agents is an important one. In our study,
aprotinin was administered to eight patients (13.6%) exposed to
clopidogrel and one patient (0.6%) without exposure. Any hemo-
static effect of this agent would be expected to reduce adverse
bleeding outcomes in the clopidogrel group, thus diminishing the
differences seen between the groups. Ever since the completion of
our study, we have started to use aprotinin routinely when
immediate surgery is unavoidable in patients with clopidogrel
exposure, and we are finding that perioperative bleeding is sub-
stantially reduced in most, but not all, cases. We echo the
sentiment that the role of preoperative antiplatelet therapy in
combination with antifibrinolytic agents is promising, but it is
a role that is still undefined. Until further studies establish the
efficacy of aggressive preoperative antiplatelet therapy, we
maintain that caution should be exercised when patients ex-
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posed to a combination of clopidogrel and aspirin present for
CABG surgery.
Rupsa R. Yee, MD, FACC
Division of Cardiology
California Pacific Medical Center
2333 Buchanan Street
San Francisco, California 94115
E-mail: phillimx@sutterhealth.org
Richard H. Hongo, MD
Jill Ley, RN, MS, CCRN
doi:10.1016/S0735-1097(03)00152-9
REFERENCE
1. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in
combination with aspirin when given before coronary artery bypass
grafting. J Am Coll Cardiol 2002;40:231–7.
1423JACC Vol. 41, No. 8, 2003 Letters to the Editor
April 16, 2003:1420–3
